Therapy related myeloid neoplasm, same but different?

Area of Science:

• Hematology
• Oncology
• Cancer Research

Background:

• Therapy-related myeloid neoplasms (t-MNs) are serious complications following cancer treatment.
• These include therapy-related acute myeloid leukemia (t-AML) and therapy-related myelodysplastic syndromes (t-MDS).

Purpose of the Study:

• To analyze prognostic factors and survival outcomes in a large cohort of patients with t-MNs.
• To evaluate the impact of different risk classifications on patient survival.

Main Methods:

• Retrospective study of 404 patients with t-MNs (204 t-AML, 200 t-MDS) from 1995-2018.
• Utilized 2010 European LeukemiaNet (ELN) classification for t-AML and International Prognostic Scoring System (IPSS) for t-MDS.
• Performed multivariate analysis to identify independent prognostic markers for overall survival (OS).

Main Results:

• Median OS was 11.9 months for both t-AML and t-MDS.
• Long-term survival was more common in t-AML (5-year OS 24.6%) compared to t-MDS (5-year OS 10.6%).
• For t-AML, intensive therapy, adverse ELN risk, cancer disease status, and poor performance status were significant OS predictors.
• For t-MDS, high IPSS score and poor performance status were independent OS markers.

Conclusions:

• Survival for t-MNs remains limited, particularly with adverse prognostic features or active malignancies.
• Intensive therapies show some benefit in specific t-MN cases.
• Prognostic classifications like ELN and IPSS are crucial for risk stratification in t-MN patients.